$32.30
▼ -10.25% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Burning Rock Biotech in the last 3 months. The average price target is $32.30, with a high forecast of $32.30 and a low forecast of $32.30. The average price target represents a -10.25% upside from the last price of $35.99.
The current consensus among 3 contributing investment analysts is to buy stock in Burning Rock Biotech.
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 13 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen Plus that targets therapy and immunotherapy, as well as immunotherapy- related biomarkers, such as microsatellite instability and tumor mutation burden, and NTRK fusions; and LungPlasma, a circulating tumor DNA liquid biopsy- based test for non-small cell lung cancer. It also offers ColonCore for testing gastrointestinal cancers; and HRDCore for testing genes associated with homologous recombination deficiency. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with major pharmaceutical companies, including AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone Pharmaceuticals, and BeiGene primarily through central laboratory and companion diagnostics development services to pharmaceutical companies. The company was founded in 2014 and is headquartered in Guangzhou, China.
Read More
